GLPwatch
Papers (12034)
Page 170 of 201, ranked by citation count.
- Highlights from JAAD Reviews: Skin in the Game: Dermatologic and Medicolegal Aspects of GLP-1 Receptor Agonists.
- Chronic social defeat stress induces a hypoglycemic shift and depression-related behaviors, both prevented by antidiabetic drugs.
- Orforglipron and the emergence of oral GLP-1 therapy for obesity: efficacy, safety, and clinical positioning.
- Semaglutide and Neovascular Age-Related Macular Degeneration among Adults with Type 2 Diabetes: An Observational Health Data Sciences and Informatics Network Study.
- Integrating GLP-1 Receptor Agonists Into Dermatology Practice: Safety and Monitoring Strategies.
- Micronutrient risk with GLP-1 receptor and dual incretin agonists in obesity: Mechanistic pathways, clinical signals, and a monitoring framework.
- Role of Oral Glucagon-Like Peptide-1 Receptor Agonists in Weight Management for Individuals With Overweight or Obesity Without Diabetes: A Network Meta-Analysis of Randomized Controlled Trials.
- [In patients with type 2 diabetes on metformin, the addition of which antihyperglycemic class among a sulfonylurea (glimepiride), a DPP-4 inhibitor (sitagliptin), a GLP-1 agonist (liraglutide), or basal insulin (glargine) is the most effective to achieve and maintain good glycemic control?]
- How does survodutide work? Plain language review of a potential new medication for obesity and liver disease.
- Saxagliptin Combined with Liraglutide vs. Saxagliptin Alone on Microinflammation and Adipokines in Obese T2DM Patients with Poor Metformin Response.
- Neuropsychiatric association of tirzepatide and semaglutide in obesity with and without type 2 diabetes.
- Peritoneal Incretin Deficiency and Tirzepatide as a Multi-Axis Adjuvant Hypothesis in Treatment-Refractory Endometriosis: A Mechanistic Framework Linking Metabolism, Immunity, Fibrosis, and Nociception.
- Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo.
- Hydrophobic ion pairing formed semaglutide designed for oral self-microemulsifying delivery in diabetes treatment.
- Retrospective Comparative Study of Oral Versus Subcutaneous Semaglutide in Patients with Type 2 Diabetes Mellitus.
- [The Beneficial Effects of Switching from Dipeptidyl Peptidase-4 Inhibitors to Dulaglutide on Plasma Glucose and Hemoglobin A1c Levels: A Case Report of Four Patients with Type 2 Diabetes].
- Clinical Characteristics Associated with Adherence and Persistence in Patients with Type 2 Diabetes Mellitus Treated with Dulaglutide.
- The Nephroprotective Effects of Dulaglutide in Patients with Type 2 Diabetes and Chronic Kidney Disease: <i>A Multicenter Saudi Arabian Study</i>.
- Semaglutide Linked With Lower Risk of Suicidal Thoughts.
- Special Considerations When Using GLP-1 Receptor Agonists in the Treatment of Obesity and Diabetes Mellitus Type 2 in Older Adults.
- Hypersensitivity Reaction to Tirzepatide With Demonstrated Tolerance to Semaglutide: A Case Report.
- Liraglutide and Recurrent Stroke by Baseline Insulin Resistance: A Post Hoc Analysis of the LAMP Trial.
- Oral delivery of GLP-1 analogues by recombinant Lactococcus lactis restores pancreatic islet structure through intestinal mucosal absorption in diabetic mice.
- Targeting Cellulite as a Metabolic-Dermal Interface: Effects of Tirzepatide and a Multi-Pathway Topical Therapy (G21) in a 12-Month Observational Study.
- Orforglipron, a Small-Molecule Glucagon-like Peptide-1 Receptor Agonist (GLP-1RA), Has Neuroprotective and Anti-Inflammatory Effects.
- Glucagon-Like Peptide-1 Receptor Agonists Inhibit the Initiation of Toxic Amyloid-β42 Aggregation.
- Cardiometabolic risk effects of weight-loss medications: An updated network meta-analysis.
- Once-weekly exenatide as a treatment for Type 2 diabetes.
- Comparative Cardiovascular Pharmacovigilance of Semaglutide and Tirzepatide: A Food and Drug Administration Adverse Event Reporting System (FAERS) Database Analysis (2022-2026).
- Transforming a protease inhibitor into a peptide Guardian: BBI-armed hydrogel beads for Oral delivery of active peptides.
- Real-world outcomes of hybrid obesity care using digital coaching and GLP-1 therapy in a multi-ethnic Asian setting.
- Knowledge, Attitudes and Practices on the Use of Antidiabetic Medications for Weight Loss: A Cross-Sectional Study in the Lebanese Population.
- Euglycemic diabetic ketoacidosis following treatment with tirzepatide and SGLT-2 inhibitors: A case report and literature review.
- Cardiovascular outcomes of semaglutide and tirzepatide in type 2 diabetes mellitus and obesity: a systematic review and meta-analysis.
- Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.
- Blockbuster obesity drug leads to better health in people with HIV.
- GLP-1 regulates osteo-adipogenic fate of BMSCs via HIF-2-AKT signaling and supports trabecular bone in glucocorticoid-induced osteoporosis.
- Advancing precision health discovery in a genetically diverse health system.
- Effects of dapagliflozin and dulaglutide on blood pressure and coronary flow in liver steatosis patients with type 2 diabetes.
- Naltrexone/Bupropion, Liraglutide, or Semaglutide as Adjuvant Therapy After Metabolic and Bariatric Surgery: An Observational Study.
- [Treatment of patients with type 2 diabetes mellitus: cardiovascular safety of incretin-based therapy supported by the ELIXA and TECOS trials].
- [Incretin-based therapy for treating patients with type 2 diabetes].
- High-yield recombinant production of the semaglutide main chain P29 intermediate using SNAC-tagged enterokinase-cleavable fusion peptides.
- Negative effects of semaglutide on bone in obese mice.
- Real-world treatment satisfaction and experience with once-weekly tirzepatide: Insights from prescribing physicians and people with obesity or overweight.
- Hemoglobin A1c levels in patients with type 2 diabetes mellitus receiving oral semaglutide with versus without proton pump inhibitors: An exploratory study.
- Peptide Mapping Using Multienzyme Digestion Strategies Integrated with LC-HRMS Workflow: A Case Study.
- Switching from subcutaneous to oral semaglutide in type 2 diabetes: A prospective study.
- Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
- Glucagon-Like Peptide-1 (GLP-1)-Based Therapies and Heart Failure Outcomes: A Scoping Review of Contemporary Randomized Controlled Trials.
- Reply.
- Exenatide through PPARδ improved hepatic insulin resistance in patients of type 2 diabetes mellitus via suppressing pyroptosis.
- NEW FOR YOU! These innovative products aim to help make diabetes self-management easier.
- GLP-1 Receptor Agonists in Cardiac Surgery: From Metabolic Drug to Potential Perioperative Cardioprotective Agent.
- Glucagon-like peptide-1 receptor agonists as a metabolic optimization strategy in surgical prehabilitation: a translational perspective.
- Effects of Semaglutide on Weight and Insulin Requirements in Two Adolescents With Type 1 Diabetes.
- Orforglipron for obesity treatment in older patients ≥65 years with or without type 2 diabetes: A post hoc subgroup analysis of the ATTAIN-1 and ATTAIN-2 trials.
- Trends in glucagon-like peptide-1 receptor agonist utilization and expenditure in Croatia.
- The Ethics of Wegovy in Pediatric Mental Health.
- Efficacy and Safety of iGlarLixi Versus IDegAsp by Baseline Age, Disease Duration and HbA1c in Chinese People With Type 2 Diabetes: Post Hoc Analyses of the Soli-D Study.